Scandion Oncology was established to address one of the most important problems in modern oncology: the treatment of cancers that have developed resistance to chemotherapy.
What makes Scandion Oncology an attractive company for investors?
- Limited investment horizon: Clinical Phase II studies will be completed within 3 years after investment.
- Potential high return: Detailed analyses from Cortris show that the current market for the chosen indications is more than EUR 4 billion in annual peak sales.
- Strong assets with patent rights: The patents underlying our two major products in development expire in 2036 and 2037.
- High unmet medical needs: More than 14 million new cases of cancer every year on a worldwide scale. Half of all patients who receive chemotherapy become resistant.
- Experienced management team: Our executive team includes a CEO with more than 25 years of biotech and pharma experience and a CSO who has authored more than 70 publications, the majority focusing on translational cancer research, biomarkers and drug resistance.
- Robust pipeline: Scandion Oncology has two major assets under development, SCO-101 and SCO-201, and more than 800 analogues for the future. The target indications for the analogues are solid tumors.
- Strong clinical data: Our lead product – SCO-101 – has successfully passed four Phase I trials without showing toxicity.
- Multiple indications: In addition to our lead product SCO-101 targeting metastatic breast cancer and colorectal cancer, we are simultaneously developing SCO-201, which will target other solid tumors.